Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV.

Downloaded from https://aidsinfo.nih.gov/guidelines on 8/26/2020

Visit the AIDSGO website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.

Downloaded from https://aidsinfo.nih.gov/guidelines on 8/26/2020
## Appendix B. Panel Roster and Financial Disclosures

### Leadership (Last updated: May 14, 2019; last reviewed: May 14, 2019)

<table>
<thead>
<tr>
<th>Member</th>
<th>Financial Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benson, Constance</td>
<td>University of California, San Diego</td>
</tr>
<tr>
<td>Brooks, John T.</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>Holmes, King</td>
<td>University of Washington School of Medicine</td>
</tr>
<tr>
<td>Masur, Henry</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>Pau, Alice</td>
<td>National Institutes of Health</td>
</tr>
</tbody>
</table>

**Note:** Members were asked to disclose all relationships from 24 months prior to the updated date. The period of reporting was from May 1, 2017, through May 1, 2019.
### Section Review Group (Last updated: January 1, 2020; last reviewed: January 1, 2020)

<table>
<thead>
<tr>
<th>Member</th>
<th>Financial Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barakat, Lydia</td>
<td>Yale University School of Medicine</td>
</tr>
<tr>
<td></td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>Campbell, Thomas*</td>
<td>University of Colorado Denver School of Medicine</td>
</tr>
<tr>
<td></td>
<td>Gilead Sciences</td>
</tr>
<tr>
<td></td>
<td>Advisory Board, Research Support</td>
</tr>
<tr>
<td></td>
<td>Janssen</td>
</tr>
<tr>
<td></td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td>Merck</td>
</tr>
<tr>
<td></td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td>ViiV</td>
</tr>
<tr>
<td></td>
<td>Advisory Board, Research Support</td>
</tr>
<tr>
<td>Healey, Letha</td>
<td>HIV/AIDS Bureau Health Resources and Services Administration</td>
</tr>
<tr>
<td></td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>Kitchell, Ellen</td>
<td>University of Texas Southwestern</td>
</tr>
<tr>
<td></td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>Robbins, Gregory</td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td></td>
<td>AIDS Clinical Trial Group (ACTG)</td>
</tr>
<tr>
<td></td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td>Biogen</td>
</tr>
<tr>
<td></td>
<td>Equity Interest</td>
</tr>
<tr>
<td></td>
<td>Citius Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td>Emergent Biosolutions</td>
</tr>
<tr>
<td></td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td>Gilead Sciences</td>
</tr>
<tr>
<td></td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td>Leonard Meron Biosciences</td>
</tr>
<tr>
<td></td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td>Pfizer</td>
</tr>
<tr>
<td></td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td>United Healthcare</td>
</tr>
<tr>
<td></td>
<td>Equity Interest</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the reviewed date. The period of reporting was from January 1, 2019, through January 1, 2020.
**Bacterial Enteric Infections** *(Last updated: August 1, 2019; last reviewed: August 1, 2019)*

<table>
<thead>
<tr>
<th>Member</th>
<th>Financial Disclosure</th>
<th>Company</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bowen, Anna</td>
<td><em>Centers for Disease Control and Prevention</em></td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Pham, Paul</td>
<td><em>Johns Hopkins University, School of Medicine &amp; Westview Urgent Care Medi Center</em></td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Sears, Cynthia*</td>
<td><em>Johns Hopkins University</em></td>
<td>United Kingdom-Cancer Research</td>
<td>Research Support</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.
Bartonellosis (Last updated: January 1, 2020; last reviewed: August 1, 2019)

<table>
<thead>
<tr>
<th>Member</th>
<th>Financial Disclosure</th>
<th>Company</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basgoz, Nesli</td>
<td></td>
<td>Harvard Medical School</td>
<td>Allergen</td>
</tr>
<tr>
<td>Chomel, Bruno</td>
<td></td>
<td>University of California Davis</td>
<td>None</td>
</tr>
<tr>
<td>Kirby, James</td>
<td></td>
<td>Harvard Medical School</td>
<td>None</td>
</tr>
<tr>
<td>Koehler, Jane</td>
<td></td>
<td>University of California San Francisco</td>
<td>UpToDate</td>
</tr>
<tr>
<td>Rose, Stacey*</td>
<td></td>
<td>Baylor College of Medicine</td>
<td>None</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.
## Mucocutaneous Candidiasis (Last updated: August 1, 2019; last reviewed: August 1, 2019)

<table>
<thead>
<tr>
<th>Member</th>
<th>Financial Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lionakis, Michail</strong></td>
<td><strong>National Institutes of Health</strong></td>
</tr>
<tr>
<td><strong>Mansour, Michael</strong></td>
<td><strong>Massachusetts General Hospital</strong></td>
</tr>
<tr>
<td><strong>Nett, Jeniel</strong></td>
<td><strong>University of Washington Madison</strong></td>
</tr>
<tr>
<td><strong>Ostrosky-Zeichner, Luis</strong></td>
<td><strong>University of Texas Houston</strong></td>
</tr>
<tr>
<td><strong>Revankar, Sanjay</strong></td>
<td><strong>Wayne State University School of Medicine</strong></td>
</tr>
<tr>
<td><strong>Sobel, Jack</strong></td>
<td><strong>Wayne State University School of Medicine</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Company</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Celularity</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>GenMark Diagnostics</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Research Support</td>
</tr>
<tr>
<td>SmartPharm</td>
<td>Consultant</td>
</tr>
<tr>
<td>UpToDate</td>
<td>Medical Writing</td>
</tr>
<tr>
<td>Vericel</td>
<td>Consultant</td>
</tr>
<tr>
<td>Burroughs Wellcome Fund</td>
<td>Research Support</td>
</tr>
<tr>
<td>Doris Duke Charitable Foundation</td>
<td>Research Support</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Research Support</td>
</tr>
<tr>
<td>Astellas</td>
<td>Advisory Board, Research Support</td>
</tr>
<tr>
<td>Amplyx</td>
<td>Research Support</td>
</tr>
<tr>
<td>Cidara</td>
<td>Advisory Board, Research Support</td>
</tr>
<tr>
<td>FZG</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>Mayne</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>Merck</td>
<td>Speaker’s Bureau</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Speaker’s Bureau</td>
</tr>
<tr>
<td>SCYNEXIS, Inc</td>
<td>Research Support</td>
</tr>
<tr>
<td>Astellas</td>
<td>Research Support</td>
</tr>
<tr>
<td>SCYNEXIS, Inc</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>UpToDate</td>
<td>Medical Writing</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.
### Community-Acquired Pneumonia  
(Last updated: January 1, 2020; last reviewed: August 1, 2019)

<table>
<thead>
<tr>
<th>Member</th>
<th>Financial Disclosure</th>
<th>Company</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cribbs, Sushma</td>
<td></td>
<td><em>Emory University</em></td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>Crothers, Kristina*</td>
<td></td>
<td><em>University of Washington</em></td>
<td>American Lung Association</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>Kobayashi, Miwako</td>
<td></td>
<td><em>Centers for Disease Control and Prevention</em></td>
<td>None</td>
</tr>
<tr>
<td>Matanock, Almea</td>
<td></td>
<td><em>Centers for Disease Control and Prevention</em></td>
<td>Gavi, The Vaccine Alliance</td>
</tr>
<tr>
<td>Miller, Robert</td>
<td></td>
<td><em>University College London, England</em></td>
<td>Gilead</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>British HIV Association</td>
</tr>
<tr>
<td>Niederman, Michael</td>
<td></td>
<td><em>Cornell University</em></td>
<td>Bayer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Merck</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Partek</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pfizer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Shionogi</td>
</tr>
<tr>
<td>Rodriguez-Barradas, Maria</td>
<td></td>
<td><em>Michael E. DeBakey VAMC and Baylor College of Medicine</em></td>
<td>None</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.
**Cryptosporidiosis and Microsporidiosis** *(Last updated: August 1, 2019; last reviewed: August 1, 2019)*

<table>
<thead>
<tr>
<th>Member</th>
<th>Financial Disclosure</th>
<th>Company</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desruisseaux, Mahalia</td>
<td>None N/A</td>
<td><em>Albert Einstein College of Medicine</em></td>
<td>N/A</td>
</tr>
<tr>
<td>Didier, Elizabeth</td>
<td>None N/A</td>
<td><em>University of California, Davis</em></td>
<td>N/A</td>
</tr>
<tr>
<td>Hlavsa, Michele</td>
<td>None N/A</td>
<td><em>Centers for Disease Control and Prevention</em></td>
<td>N/A</td>
</tr>
<tr>
<td>Ward, Honorine</td>
<td>None N/A</td>
<td><em>Tufts University School of Medicine</em></td>
<td>N/A</td>
</tr>
<tr>
<td>Weiss, Louis*</td>
<td>None N/A</td>
<td><em>Albert Einstein College of Medicine</em></td>
<td>N/A</td>
</tr>
<tr>
<td>White, A. Clinton</td>
<td>None N/A</td>
<td><em>University of Texas Medical Branch</em></td>
<td>N/A</td>
</tr>
<tr>
<td>Xiao, Lihua</td>
<td>None N/A</td>
<td><em>Centers for Disease Control and Prevention</em></td>
<td>N/A</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.
# Geographic OIs (Chagas Disease, Isosporiasis, Leishmaniasis, Malaria, Talaromycosis)

*(Last updated: August 1, 2019; last reviewed: August 1, 2019)*

<table>
<thead>
<tr>
<th>Member</th>
<th>University of Toronto Department of Medicine</th>
<th>None</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dhanireddy, Shireesh*</td>
<td>University of Washington School of Medicine</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Le, Thuy</td>
<td>Duke University</td>
<td>Gilead Sciences</td>
<td>Research Support</td>
</tr>
<tr>
<td>Montgomery, Susan</td>
<td>Centers for Disease Control and Prevention</td>
<td>None</td>
<td>N/A</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the reviewed date. The period of reporting was from August 1, 2018, through August 1, 2019.
### Hepatitis B Virus Infection (Last updated: August 1, 2019; last reviewed: August 1, 2019)

<table>
<thead>
<tr>
<th>Member</th>
<th>University of California, Los Angeles</th>
<th>AbbVie</th>
<th>Research Support</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bhattacharya, Debika</td>
<td>National Institutes of Health</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Harris, Aaron</td>
<td>Centers for Disease Control and Prevention</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Hawkins, Claudia</td>
<td>Northwestern University</td>
<td>National Institutes of Health</td>
<td>Research Support</td>
</tr>
<tr>
<td>Peters, Marion</td>
<td>University of California San Francisco</td>
<td>Abbott</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>Thio, Chloe*</td>
<td>Johns Hopkins University</td>
<td>Antios</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Sanofi U.S.</td>
<td>Research Support</td>
<td></td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.
### Hepatitis C Virus Infection (Last updated: January 1, 2020; last reviewed: August 1, 2019)

<table>
<thead>
<tr>
<th>Member</th>
<th>Financial Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Company</strong></td>
</tr>
<tr>
<td>Bansal, Meena</td>
<td>Mount Sinai Hospital</td>
</tr>
<tr>
<td>Kim, Arthur</td>
<td>Harvard Medical School</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Nina</td>
<td>University of Washington</td>
</tr>
<tr>
<td>Naggie, Susanna</td>
<td>Duke University</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulkowski, Mark*</td>
<td>Johns Hopkins University</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Villanueva, Merceditas</td>
<td>Yale University School of Medicine</td>
</tr>
<tr>
<td>Wyles, David</td>
<td>Denver Health Medical Center and University of Colorado School of Medicine</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the reviewed date. The period of reporting was from August 1, 2018, through August 1, 2019.
# Herpes (Cytomegalovirus, Herpes Simplex Virus, Human Herpesvirus-8, and Varicella-Zoster Virus) *(Last updated: January 1 2020; last reviewed: August 1, 2019)*

<table>
<thead>
<tr>
<th>Member</th>
<th>Institution</th>
<th>Financial Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Member</strong></td>
<td><strong>Company</strong></td>
<td><strong>Relationship</strong></td>
</tr>
<tr>
<td>Durand, Christine</td>
<td>Johns Hopkins</td>
<td>AbbVie</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gilead</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ViiV Healthcare</td>
</tr>
<tr>
<td>Gnann, John</td>
<td>Medical University of South Carolina</td>
<td>BioCryst</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Holland, Gary</td>
<td>University of California, Los Angeles</td>
<td>None</td>
</tr>
<tr>
<td>Johnston, Christine*</td>
<td>University of Washington</td>
<td>Sanofi-Pasteur</td>
</tr>
<tr>
<td></td>
<td></td>
<td>UpToDate</td>
</tr>
<tr>
<td>Parsons, Christopher</td>
<td>Pardee Hospital, University of North Carolina Health Systems</td>
<td>None</td>
</tr>
<tr>
<td>Phipps, Warren</td>
<td>University of Washington School of Medicine</td>
<td>None</td>
</tr>
<tr>
<td>Ross, Shannon</td>
<td>University of Alabama at Birmingham</td>
<td>Children's Hospital of Alabama Kaul Pediatric Research Institute</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Merck</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Meridian Bioscience</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td>Van Wagoner, Nicholas</td>
<td>University of Alabama at Birmingham</td>
<td>Genocea</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sanofi-Pasteur</td>
</tr>
<tr>
<td>Wohi, David</td>
<td>University of North Carolina at Chapel Hill</td>
<td>Gilead</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Janssen</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Merck</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ViiV Healthcare</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.
### Human Papillomavirus Disease

*Last updated: January 1, 2020; last reviewed: August 1, 2019*

#### Note:

Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.

<table>
<thead>
<tr>
<th>Member</th>
<th>Company</th>
<th>Financial Disclosure</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brown, Darron</td>
<td><em>Indiana University School of Medicine</em></td>
<td>Merck, Productive Data Solutions, Inc.</td>
<td>Research Support, Consultant</td>
</tr>
<tr>
<td>Cu-Uvin, Susan*</td>
<td><em>Brown University</em></td>
<td>AIDS Malignancy Consortium, National Institutes of Health, United Nations Population Fund</td>
<td>Data Safety Monitoring Board, Research Support, Research Support</td>
</tr>
<tr>
<td>Dunne, Eileen</td>
<td><em>Centers for Disease Control and Prevention</em></td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Einstein, Mark</td>
<td><em>Rutgers New Jersey Medical School</em></td>
<td>Advaxis, Altum Pharma, AstraZeneca, Becton-Dickinson, Cynvec, Hologic, Inovio, J&amp;J, Merck, Papivax, PDS Biotechnologies, Pfizer, Roche</td>
<td>Research Support, Consultant, Research Support, Consultant, Research Support, Consultant, Consultant, Research Support, Consultant, Research Support, Consultant, Advisory Board</td>
</tr>
<tr>
<td>Massad, L. Stewart</td>
<td><em>Washington University School of Medicine</em></td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Moscicki, Anna Barbara</td>
<td><em>University of California, Los Angeles</em></td>
<td>Antiva, GlaxoSmithKline, Merck, Patient-Centered Outcomes Research Institute</td>
<td>Advisory Board, Advisory Board, Advisory Board, Research Support</td>
</tr>
<tr>
<td>Palefsky, Joel</td>
<td><em>University of California, San Francisco</em></td>
<td>Antiva Biosciences, Janssen Pharmaceuticals, Merck, Ubio, Vir Biotechnology, Virion Therapeutics</td>
<td>Research Support, Speakers Bureau, Advisory Board, Research Support, Advisory Board, Equity Interest, Consultant, Equity Interest, Advisory Board, Equity Interest</td>
</tr>
<tr>
<td>Stier, Elizabeth</td>
<td><em>Boston University Medical Center</em></td>
<td>Antiva, Inovio</td>
<td>Consultant, Research Support</td>
</tr>
<tr>
<td>Strickler, Howard</td>
<td><em>Albert Einstein College of Medicine</em></td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Weiser, John</td>
<td><em>Centers for Disease Control and Prevention</em></td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Wilkin, Timothy</td>
<td><em>Weill Cornell Medical College</em></td>
<td>GlaxoSmithKline/ViiV</td>
<td>Consultant, Research Support</td>
</tr>
</tbody>
</table>

* Group lead
### Immunizations (Last updated: January 1, 2020; last reviewed: August 1, 2019)

<table>
<thead>
<tr>
<th>Member</th>
<th>Financial Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dhanireddy, Shireesha *</td>
<td>University of Washington School of Medicine, None, N/A</td>
</tr>
<tr>
<td>Neblett Fanfair, Robyn</td>
<td>Centers for Disease Control and Prevention, None, N/A</td>
</tr>
<tr>
<td>Ortiz, Justin</td>
<td>University of Maryland School of Medicine, Pfizer, Speaking Compensation, Advisory Board</td>
</tr>
<tr>
<td>Peters, Philip</td>
<td>Centers for Disease Control and Prevention, None, N/A</td>
</tr>
<tr>
<td>Solomon, Daniel</td>
<td>Harvard University, None, N/A</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the reviewed date. The period of reporting was from August 1, 2018, through August 1, 2019.
### Invasive Mycoses (Cryptococcosis, Histoplasmosis, Coccidioidomycosis)  
(Last updated: August 1, 2019; last reviewed: August 1, 2019)

<table>
<thead>
<tr>
<th>Member</th>
<th>Company</th>
<th>Financial Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ampel, Neil</td>
<td>University of Arizona</td>
<td>None N/A</td>
</tr>
<tr>
<td>Boulware, David</td>
<td>University of Minnesota</td>
<td>Appili Therapeutics Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>bioMerieux Speaker’s Bureau</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gilead Research Support</td>
</tr>
<tr>
<td>Hamill, Richard</td>
<td>Baylor College of Medicine</td>
<td>None N/A</td>
</tr>
<tr>
<td>Kauffman, Carol*</td>
<td>University of Michigan and VA Ann Arbor Healthcare System</td>
<td>Veterans Education and Research Association of Michigan Research Support</td>
</tr>
<tr>
<td>Miceli, Marisa</td>
<td>University of Michigan</td>
<td>Astellas Advisory Board, Consultant, Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SCYNEXIS Consultant, Research Support</td>
</tr>
<tr>
<td>Pappas, Peter</td>
<td>University of Alabama at Birmingham</td>
<td>Astellas Pharma Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cidara Therapeutics Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Merck Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SCYNEXIS Advisory Board, Research Support</td>
</tr>
<tr>
<td>Perfect, John</td>
<td>Duke University</td>
<td>Amplyx Pharmaceuticals Advisory Board, Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Astellas Advisory Board, Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Matinas BioPharma Holdings, Inc Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Merck Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Minnetronix Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mycova Pharmaceuticals Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pfizer Research Support</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.
Disseminated *Mycobacterium avium* Complex Disease  *(Last updated: August 1, 2019; last reviewed: August 1, 2019)*

<table>
<thead>
<tr>
<th>Member</th>
<th>Financial Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benson, Constance*</td>
<td>Dr. Benson has served on an advisory and a data monitoring board for GlaxoSmithKline/ViiV Healthcare and received research grants awarded to her institution from Gilead Sciences, Inc. and DNA Electronics, Inc. Her spouse has served as a consultant to CytoDyn, Gilead Sciences, Inc, Pfizer, and Vir Biotechnology; has received grant support from Gilead Sciences, Inc; and holds stock or stock options in Antiva Biosciences and CytoDyn.</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.
### Mycobacterium tuberculosis Infection and Disease

*(Last updated: January 1, 2020; last reviewed: August 1, 2019)*

<table>
<thead>
<tr>
<th>Member</th>
<th>Financial Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Company</td>
</tr>
<tr>
<td>Brust, James*</td>
<td>Albert Einstein College of Medicine</td>
</tr>
<tr>
<td>Dooley, Kelly</td>
<td>Johns Hopkins University</td>
</tr>
<tr>
<td>Goswami, Neela</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>Heysell, Scott</td>
<td>University of Virginia</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Maartens, Gary</td>
<td>University of Cape Town, South Africa</td>
</tr>
<tr>
<td>Meintjes, Graeme</td>
<td>University of Cape Town, South Africa</td>
</tr>
<tr>
<td>Shah, Sarita</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>Sterling, Timothy</td>
<td>Vanderbilt University Medical Center</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.
**Pharmacology** *(Last updated: August 1, 2019; last reviewed: August 1, 2019)*

<table>
<thead>
<tr>
<th>Member</th>
<th>Financial Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dooley, Kelly</td>
<td><em>Johns Hopkins University School of Medicine</em></td>
</tr>
<tr>
<td>George, Jomy</td>
<td><em>National Institutes of Health</em></td>
</tr>
<tr>
<td>Kuriakose, Safia</td>
<td><em>National Institutes of Health</em></td>
</tr>
<tr>
<td>Pau, Alice*</td>
<td><em>National Institutes of Health</em></td>
</tr>
<tr>
<td>Peloquin, Charles</td>
<td><em>University of Florida</em></td>
</tr>
<tr>
<td>Pham, Paul</td>
<td><em>Johns Hopkins University, School of Medicine &amp; Westview Urgent Care Medi Center</em></td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.
**Progressive Multifocal Leukoencephalopathy** *(Last updated: January 1, 2020; last reviewed: August 1, 2019)*

<table>
<thead>
<tr>
<th>Member</th>
<th>University of Alabama at Birmingham</th>
<th>Financial Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agnihotri, Shruti</td>
<td></td>
<td>Company: None, Relationship: N/A</td>
</tr>
<tr>
<td>Cinque, Paola</td>
<td>San Raffaele Scientific Institute, Milan, Italy</td>
<td>Company: Gilead, Relationship: Research Support, Janssen, Relationship: Consultant, Pfizer, Relationship: Data Safety Monitoring Board, Shire, Relationship: Data Safety Monitoring Board</td>
</tr>
<tr>
<td>Marra, Christina</td>
<td>University of Washington School of Medicine</td>
<td>Company: International NeuroHIV Cure Consortium, Relationship: Consultant, Johnson &amp; Johnson, Relationship: Equity Interest, McKesson, Relationship: Equity Interest, NIH, Relationship: Research Support, UpToDate, Relationship: Royalties, Wolters Kluwer, Relationship: Royalties</td>
</tr>
<tr>
<td>Miro, Jose M.</td>
<td>Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain</td>
<td>Company: None, Relationship: N/A</td>
</tr>
<tr>
<td>Nath, Avindra</td>
<td>National Institutes of Health</td>
<td>Company: None, Relationship: N/A</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.
**Pneumocystis Pneumonia** *(Last updated: August 1, 2019; last reviewed: August 1, 2019)*

<table>
<thead>
<tr>
<th>Member</th>
<th>Financial Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Company</strong></td>
</tr>
<tr>
<td>Crothers, Kristina</td>
<td>Yale University School of Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Furrer, Hansjakob</td>
<td>Universitatsspital Bern, Switzerland</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Helweg-Larsen, Jannik</td>
<td>Rigshospitalet, Copenhagen University, Denmark</td>
</tr>
<tr>
<td>Huang, Laurence</td>
<td>University of California, San Francisco</td>
</tr>
<tr>
<td>Kalapila, Aley</td>
<td>Emory University</td>
</tr>
<tr>
<td>Kovacs, Joe*</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Miller, Robert</td>
<td>University College London, England</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Morris, Alison</td>
<td>University of Pittsburgh Medical School</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.
### Pregnancy (Last updated: January 1, 2020; last reviewed: August 1, 2019)

<table>
<thead>
<tr>
<th>Member</th>
<th>Financial Disclosure</th>
<th>Company</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anderson, Jean</td>
<td>Johns Hopkins University</td>
<td>DBKmed</td>
<td>Research Support</td>
</tr>
<tr>
<td>Bunge, Katherine</td>
<td>UPMC Magee-Womens Hospital</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Chakhtoura, Nahida</td>
<td>National Institutes of Health</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Hughes, Brenna</td>
<td>Women &amp; Infants Hospital of Rhode Island</td>
<td>Merck</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>Watts, Heather*</td>
<td>Office of the Global AIDS Coordinator</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Wright, Rodney</td>
<td>Albert Einstein College of Medicine</td>
<td>None</td>
<td>N/A</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the reviewed date. The period of reporting was from August 1, 2018, through August 1, 2019.
**Syphilis** (Last updated: August 1, 2019; last reviewed: August 1, 2019)

<table>
<thead>
<tr>
<th>Member</th>
<th>Financial Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bolan, Gail</td>
<td><em>Centers for Disease Control and Prevention</em></td>
</tr>
<tr>
<td>Ghanem, Khalil</td>
<td><em>Johns Hopkins University</em></td>
</tr>
<tr>
<td>Hollier, Lisa</td>
<td><em>Baylor College of Medicine</em></td>
</tr>
<tr>
<td>Hook, Edward W.</td>
<td><em>University of Alabama at Birmingham</em></td>
</tr>
<tr>
<td>Sena, Arlene</td>
<td><em>University of North Carolina</em></td>
</tr>
<tr>
<td>Stoner, Brad</td>
<td><em>Washington University School of Medicine</em></td>
</tr>
<tr>
<td>Workowski, Kim*</td>
<td><em>Emory University</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Company</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Research Support</td>
</tr>
<tr>
<td>Gilead Sciences</td>
<td>Research Support</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>Research Support</td>
</tr>
<tr>
<td>Hologic, Inc</td>
<td>Speaking Compensation, Advisory Board</td>
</tr>
<tr>
<td>Lupin Pharmaceuticals, Inc</td>
<td>Research Support</td>
</tr>
<tr>
<td>UpToDate</td>
<td>Royalties</td>
</tr>
<tr>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Acuris</td>
<td>Research Support</td>
</tr>
<tr>
<td>Gilead Sciences</td>
<td>Advisory Board, Research Support</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>Advisory Board, Research Support</td>
</tr>
<tr>
<td>Janssen Pharmaceuticals</td>
<td>Advisory Board</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.
Toxoplasma gondii Encephalitis (Last updated: January 1, 2020; last reviewed: August 1, 2019)

<table>
<thead>
<tr>
<th>Member</th>
<th>Financial Disclosure</th>
<th>Company</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boyd, Sarita</td>
<td></td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Chow, Felicia</td>
<td></td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Kovacs, Joe*</td>
<td>National Institutes of Health</td>
<td>Matinas BioPharma</td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Merck</td>
<td>Research Support</td>
</tr>
<tr>
<td>Kuruppu, Janaki</td>
<td>National Institutes of Health</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Lai, Leon</td>
<td>Washington Hospital Center</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Miro, Jose M.</td>
<td>Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Podzamczer, Daniel</td>
<td>Hospital Universitari de Bellvitge, Barcelona, Spain</td>
<td>None</td>
<td>N/A</td>
</tr>
</tbody>
</table>

* Group lead

**Note:** Members were asked to disclose all relationships from 12 months prior to the reviewed date. The period of reporting was from August 1, 2018, through August 1, 2019.